白云山(00874.HK) 公布，分公司广州白云山医药集团白云山制药总厂，于近日接获国家药品监督管理局核准签发的《药品补充申请批准通知书》，“阿奇霉素胶囊”已通过仿制药质量和疗效一致性评价。
据介绍，“阿奇霉素”主要用于治疗化脓性链球菌引起的急性咽炎、急性扁桃体炎；敏感细菌引起的鼻窦炎、中耳炎、急性支气管炎、慢性支气管炎急性发作；肺炎链球菌、流感嗜血杆菌以及肺炎支原体所致的肺炎；沙眼衣原体及非多种耐药淋病奈瑟菌所致的尿道炎和宫颈炎；敏感细菌引起的皮肤软组织感染等。
截至昨日(18日)，白云山制药总厂在“阿奇霉素胶囊”研发项目上，已投入约599.63万元人民币作研发费用。(js/k)
(港股报价延迟最少十五分钟。沽空资料截至 2024-09-17 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.